Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035906 · ClinicalTrials.gov registry record · Phase 2
Research Study in Patients With Persistent Macular Edema
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 315
- Enrollment target
NCT00035906 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 315 participants.
The verdict
NCT00035906, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 315 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects. Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision. There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.
Interventions
- DRUG DEX PS DDS®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2001-10 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035906
The ClinicalTrials.gov registry entry for NCT00035906 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DEX PS DDS® is the first listed.
NCT00035906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035906 about?
NCT00035906 is a clinical study titled "Research Study in Patients With Persistent Macular Edema". The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects. Macular edema is a condition th...
What is the current status of trial NCT00035906?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 315 participants. The study started on 2001-10. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00035906?
The interventions under investigation include: DEX PS DDS® (DRUG).
Who is sponsoring clinical trial NCT00035906?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.